bioXXmed AG (FRA:T5O)

Market Cap	209.34K -64.7%
Revenue (ttm)	16.73K +379.0%
Net Income	-365.39K
EPS	-1.34
Shares Out	271.87K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18
Open	0.7550
Previous Close	0.7700
Day's Range	0.7550 - 0.8100
52-Week Range	0.0050 - 2.7500
Beta	4.99
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 3, 2026

About bioXXmed AG

bioXXmed AG, an investment company, invests in biotechnology or medical technology companies with equity or debt capital. It engages in the development of products for the diagnosis, alleviation, or cure of diseases through investments. The company was formerly known as CytoTools AG and changed its name to bioXXmed AG in September 2022. bioXXmed AG was founded in 2000 and is based in Heidelberg, Germany.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: T5O

Financial Performance

In 2025, bioXXmed AG's revenue was 16,731, an increase of 378.99% compared to the previous year's 3,493. Losses were -365,390, -63.35% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 15, 2026

Data Sources Report a data error